Compare JFrog Ltd. Ordinary Shares (FROG) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JFrog Ltd. Ordinary Shares vs Merck & Co., Inc. — how do they compare? JFrog Ltd. Ordinary Shares trades at $97.61 (market cap $12.10B), while Merck & Co., Inc. trades at $142.35 (market cap $352.29B). The key difference: Merck & Co., Inc. is far larger — about 29.1× JFrog Ltd. Ordinary Shares's market cap, and Merck & Co., Inc. pays a 2.38% dividend while JFrog Ltd. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold JFrog Ltd. Ordinary Shares for 0 Days and Merck & Co., Inc. for 98 Days on average.
| FROG | MRK | |
|---|---|---|
Market Cap | $12.10B | $352.29B |
Volume | 773,694 | 6,348,796 |
Sector | Technology | Health |
52-Week High | $104.03 | $156.43 |
52-Week Low | $34.75 | $82.49 |
Typical Hold Time | 0 Days | 98 Days |
Enterprise Value | $11.29B | $399.05B |
Dividend Yield | — | 2.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Merck (MRK) trades at $142.40, up 0.33% on the day, with a bearish technical signal but strong analyst support. The company reported revenue of $65.0B in 2025 with a net income margin of 28.07%, though 2026 projections show a sharp decline to 4.76%. Recent acquisition activity includes the tender offer for Terns Pharmaceuticals to bolster its oncology pipeline, while cash flow trends indicate significant investing outflows in 2026.
The outlook is mixed: robust fundamentals and a consensus price target of $159.59 suggest upside, but high valuation ratios (P/E 114.23) and projected earnings volatility pose risks. Investors should weigh strong institutional buying against technical weakness and competitive pressures in the pharma sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JFrog Ltd. Ordinary Shares
JFrog provides software supply chain tools that help developers manage, secure, and distribute software packages. Its platform is used across development and deployment workflows.
Read more on FROG →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
